Next-generation sequencing contract analysis
ChIP-seq is an analytical method that can identify genomic regions where DNA-binding proteins, such as transcription factors, and histones that have specific modifications are bound. It identifies genome-wide DNA binding sites for transcription factors and other proteins. It explores the mechanisms of gene expression regulation through epigenetics, such as histone methylation. It provides candidate biomarkers for cancer and complex diseases. 【Features】 ■ Identifies genome-wide DNA binding sites for proteins ■ Explores mechanisms of gene expression regulation ■ Provides candidate biomarkers for complex diseases *For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
【Contracted Service Contents】 ■ Experimental Design ■ Quality Check of ChIP DNA ■ Library Preparation ■ Sequencing ■ Data Analysis ■ Delivery Shipping *For more details, please refer to the catalog or feel free to contact us.
Price range
P2
Delivery Time
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（3）
Download All Catalogs
Company information
Danaform Inc. is a company established in 1998, based on the RIKEN Venture System of the National Research and Development Agency RIKEN, with Yoshihide Hayasaki from RIKEN (who has been the representative director of Danaform Inc. since 2021) at its core. The company is actively engaged in gene analysis and genetic testing, focusing on technologies co-developed by Danaform and RIKEN, including contract analysis using next-generation sequencers such as CAGE-seq and RNA-seq, the sale of fluorescent reagents Eprobe capable of SNP detection, and the sale of various clones, boasting a significant inventory. Moving forward, we aim to refine our proprietary technologies and strive for higher quality research and manufacturing as experts in the field of genetics, with the hope of contributing to people's health.